Scarica l'app Stockscreener
4.92
4.84%
-0.25
Dopo l'orario di chiusura:
4.93
0.010
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$5.17
Aprire:
$4.955
Volume 24 ore:
37.41M
Relative Volume:
1.67
Capitalizzazione di mercato:
$2.23B
Reddito:
$64.60M
Utile/perdita netta:
$-377.75M
Rapporto P/E:
-3.1742
EPS:
-1.55
Flusso di cassa netto:
$-335.64M
1 W Prestazione:
-10.38%
1M Prestazione:
+9.09%
6M Prestazione:
-29.21%
1 anno Prestazione:
-47.88%
Intervallo 1D:
$4.84
$5.15
Intervallo di 1 settimana:
$4.84
$6.07
Portata 52W:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Confronta RXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.92 | 2.23B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss - Investing.com UK
Insmed surges on lung drug data; Recursion cuts staff - Yahoo Finance
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - MSN
Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI - MSN
Recursion to lay off 20% of workforce amid biotech funding woes - MSN
Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday - MSN
After pipeline cull, AI drug developer Recursion cuts staff by 20% - FirstWord Pharma
Recursion Pharma to reduce workforce by 20% - MSN
Recursion Eliminating 20% of Workforce, Citing Pipeline Pruning and Capital Markets - Genetic Engineering and Biotechnology News
Recursion Pharmaceuticals Stock Surges After Company Lays Off 20% Workforce: Retail Predicts ‘Blue Skies’ Ahead - MSN
Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening? - Benzinga
Recursion Downsizes by 20% To Boost Cash Position - BioSpace
Recursion lays off 20% of staff in wake of pipeline cutbacks - Fierce Biotech
Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky (RXRX) - Seeking Alpha
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn - 1470 & 100.3 WMBD
Recursion Cuts 20% of Workforce, Extends Cash Runway to Late 2027 - marketscreener.com
Recursion Pharma to reduce workforce by 20% (RXRX:NASDAQ) - Seeking Alpha
Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development - Value The Markets
Recursion Pharmaceuticals (RXRX) Implements Workforce and Operat - GuruFocus
Recursion Pharmaceuticals Announces Workforce Reduction Strategy - TipRanks
Recursion Pharmaceuticals announces 20% workforce reduction - TipRanks
Recursion Pharmaceuticals Announces Personnel And Infrastructure ReductionSEC Filing - marketscreener.com
15 Stocks That Stole The Show Last Week - Insider Monkey
Recursion rises on launch of Boltz-2 in partnership with MIT - MSN
Why Recursion Pharmaceuticals (RXRX) Soared On Friday - Insider Monkey
10 Stocks Are Dominating Like Wall Street Titans - Insider Monkey
Recursion Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:RXRX - Benzinga
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas - mx.advfn.com
Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT - Benzinga
Recursion Pharmaceuticals shares surge on AI model release By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals shares surge on AI model release - Investing.com
Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks
Recursion Pharmaceuticals (RXRX) Sees Surge in Bullish Options Activity | RXRX Stock News - GuruFocus
Recursion (RXRX) Shares Jump on New Biomolecular Model Launch - GuruFocus
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy - The Globe and Mail
July 25th Options Now Available For Recursion Pharmaceuticals (RXRX) - Nasdaq
Recursion Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RXRX) - Defense World
These 10 Stocks Are On Fire Right Now - Insider Monkey
AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names – Company Announcement - Financial Times
Recursion Pharmaceuticals (RXRX) Sees Surge in Bullish Options A - GuruFocus
Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Ameriprise Financial Inc. Acquires 29,034 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.1% – Here’s What Happened - Defense World
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? - MSN
Recursion to Participate in Upcoming Investor Conferences - Yahoo Finance
Did Jim Cramer Nail or Miss These 11 Stock Predictions? - Insider Monkey
Nuveen Asset Management LLC Cuts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):